Drug treatments

• 

Genes reveal risk of recurrence of kidney cancer

By Sharon Deveson Kell|2023-02-27T10:37:25+00:0027 Feb 2023|Drug treatments|

Looking at a person's DNA using a technique called DNA [...]

Read More

Comments Off on Genes reveal risk of recurrence of kidney cancer

• 

Adjuvant nivolumab plus ipilimumab in localised kidney cancer

By Sharon Deveson Kell|2023-02-27T10:20:33+00:0027 Feb 2023|Drug treatments|

A recent phase 3 study called CheckMate 914 has shown [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab in localised kidney cancer

• 

ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

By Sharon Deveson Kell|2023-02-23T14:39:48+00:0023 Feb 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

• 

ASCO GU 2023: Outcomes of patients with kidney cancer brain metastases treated with first-line therapies

By Sharon Deveson Kell|2023-02-22T09:46:42+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Outcomes of patients with kidney cancer brain metastases treated with first-line therapies

• 

ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

By Sharon Deveson Kell|2023-02-22T09:34:55+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

• 

ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-02-22T09:52:33+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

• 

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

By Sharon Deveson Kell|2023-01-24T09:57:36+00:0024 Jan 2023|Drug treatments|

Non-clear cell kidney cancer is a group of different subtypes [...]

Read More

Comments Off on Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

• 

Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

By Sharon Deveson Kell|2023-01-17T08:22:55+00:0017 Jan 2023|Drug treatments|

In this study, real world data is used to compare [...]

Read More

Comments Off on Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

• 

Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

By Sharon Deveson Kell|2023-01-12T15:18:26+00:0012 Jan 2023|Drug treatments|

A recent paper published in The Oncologist has shown that [...]

Read More

Comments Off on Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

• 

Does neoadjuvant therapy improve outcomes in localised kidney cancer?

By Sharon Deveson Kell|2023-01-12T09:51:58+00:0012 Jan 2023|Drug treatments|

At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]

Read More

Comments Off on Does neoadjuvant therapy improve outcomes in localised kidney cancer?